Korean plastic surgery trends in 2026: natural change, explained

What “natural change” means in 2026

Worldwide, cosmetic surgery has stopped growing and is changing shape. The International Society of Aesthetic Plastic Surgery (ISAPS) counted 17.9 million surgical procedures in 2025, 0.4% fewer than in 2024, while fat grafting to the face rose 60.2% and facelifts 54.7% compared with 2021. In the United States, facial fat grafting grew 39% in 2025, the largest gain of any procedure the American Society of Plastic Surgeons (ASPS) tracks, and its president described patients as “seeking authentic restoration rather than transformation”.

Korea follows the same line. In the ISAPS 2025 survey, fat grafting to the face was Korea's second most common operation after eyelid surgery. Korea's Ministry of Health and Welfare counted 2,011,822 foreign patients in 2025: 62.9% of visits were to dermatology and 11.2% to plastic surgery. Indonesian patients more than doubled, to 21,257, and most of them came for skin care rather than surgery.

In a Seoul consultation, “natural” usually means three things: a change sized to your face rather than to a fashion, your own tissue instead of an implant where that is safe, and skin quality treated alongside shape.

What Korean patients are paying for: our count

To see whether these trends show up in Korea itself, we counted entries on a well-known Korean plastic-surgery community where members post what they paid for a procedure. Each figure is the number of entries whose procedure name contains the term, per 1,000 of all entries posted in the same half-year, so a busier site does not look like a trend.

Read this as a signal, not as market statistics. It is self-reported data from one Korean community, mostly from Korean patients, and an entry is a price someone chose to post, not a counted operation. Names vary, one entry can match two rows, and small counts swing easily.

What Korean searches show

Searches are a second view. We compared search interest on Naver, Korea's main search engine, using its public DataLab tool, and on Google Trends for Korea. Both report relative interest rather than counts, so these numbers compare terms and periods with each other, not with the price entries above.

Google, for comparison

All three sources agree on the main point: thread lifts are not growing, and interest has moved to devices such as Shurink and Onda. They differ on details; Thermage rose in the price entries but fell in Naver searches.

1. Nose: your own cartilage, and keeping what works

Korean rhinoplasty has long relied on silicone implants for the bridge. The direction now is more of your own tissue: septal, ear or rib cartilage, used alone or together with an implant. In our count, entries naming the patient's own rib cartilage rose from 3.0 to 5.0 per 1,000 and ear cartilage from 0.9 to 2.1–2.9, while silicone stayed in steady use.

The evidence supports the shift. A 2026 meta-analysis of 10 studies (7,019 patients) found infection markedly less likely with autologous grafts than with silicone or Gore-Tex implants, which showed more infection and extrusion over long follow-up. Rib cartilage has its own trade-offs: in a 2022 meta-analysis of 1,648 patients, warping occurred in 3.05%, resorption in 1.2% and a thickened chest scar in 2.08%.

Preservation rhinoplasty lowers a hump by reshaping beneath it instead of removing it. Reviews report satisfaction of 84% to 100% and about two revisions per 100 patients; a 2025 meta-analysis found fewer bridge irregularities, but a hump that remained or returned more often than with the traditional method. It is a way to reduce a nose, so most visitors who want more height will still need augmentation. See Rhinoplasty for the options and stay length.

2. Revision rhinoplasty: a specialty, not a rising share

Clinic marketing often says revisions are booming. The Korean literature does show real need: contracture, a tight, shortened nose after earlier surgery, is described as one of the most severe complications in East Asian patients, and silicone capsule problems are a common reason to operate again.

In our count, though, revision entries fell steadily, from 34.1 to 20.9 per 1,000 over two years, while general rhinoplasty entries held at about 8 to 9. What Seoul offers is depth of experience with revisions, often rebuilt with rib cartilage, rather than a growing trend.

Considering a revision? Bring your earlier operation notes and any scans, find out which implant was used if you can, and expect a longer stay than for a first operation.

3. Lifting: smaller operations, and more done without surgery

A mini lift, a shorter-scar facelift for early sagging, fits the natural brief. ASPS describes it as suited to people in their mid-30s to late 40s, with a shorter scar and downtime and results that last several years. A review of one short-scar technique (the MACS lift, 739 patients) reported no major complications, but only a limited effect on the neck.

Korean entries tell a more nuanced story. Mini-lift entries fell from 2.1 to 0.5 per 1,000 and thread lifts from 5.6 to about 4, while full facelifts held at about 2. The growth went to energy devices: Ulthera rose from 8.6 to about 11, Thermage from 2.6 to 5.5, and the newer microwave device Onda from 0.8 to 9.9. Surgical lifting held up better than the mini lift: forehead lifts stayed at about 5 per 1,000, sub-brow lifts and neck lifts grew, and Endotine, mostly used to fix a midface lift, appeared in 2026. In Naver searches, facelift and forehead lift held steady while Ulthera fell by about a third. Shurink, a Korean focused-ultrasound device, held at about 10; smaller devices such as Titanium and Density grew; InMode fell from 20.7 to about 14. Thread lifts fell as a whole rather than giving way to newer threads: entries naming a thread brand stayed at about 1 per 1,000 or less, and Korean searches for the main thread brands also fell. Part of the drop follows fewer thread lifts sold together with facial liposuction. A Korean booking platform reported lifting as the most searched category in early 2026, ahead of filler and Botox.

Threads remain a reasonable short-term option. A meta-analysis of 26 studies found temporary swelling in 35% of patients and dimpling in 10%, with satisfaction falling from 98% just after treatment to 88% at six months; for absorbable threads, studies have followed patients for up to two years. Compare Facelift, Thread lift and the devices in Rejuran vs Ulthera vs Thermage vs Juvelook. For how surgery, threads and devices differ, see Face lifting: surgical or non-surgical?

4. Volume for balance: fat grafting and collagen stimulators

Instead of filling one feature, the 2026 approach looks at proportion: a flat temple, a hollow under the eye, a cheek that has lost fullness. Fat grafting uses your own fat for this. Only part of it stays: a review of 27 studies found 26% to 83% of the volume retained, about 47% on average, which is why a second session is sometimes planned. Fat grafting to the face is not risk-free either; a 2025 review of temple grafting collected 22 serious cases of fat blocking a blood vessel, so ask who performs it and how.

Collagen stimulators work more slowly. Injected particles (poly-L-lactic acid such as Sculptra, or the PDLLA in Juvelook) prompt the skin to build collagen over weeks, and a 2025 review found effects lasting up to 25 months for poly-L-lactic acid. In our count, Juvelook rose from 5.2 to about 8 per 1,000 and Sculptra from 0.7 to 2.4, while fat grafting held steady at 11 to 13. See Fat grafting and, for under-eye hollows, Under-eye fat repositioning.

5. Skin boosters become the main event

This is the clearest trend in every data set. Dermatology accounts for most foreign patient visits to Korea, and a Taiwanese Vogue editor told Vogue Korea in 2026 that Rejuran had become a “megatrend” there within two years. In our count, Rejuran, a polynucleotide booster, nearly doubled from 5.3 to about 10 per 1,000.

Re2O (리투오), launched in late 2024, went from no entries to 3.6 per 1,000 in two years. It is made from donated human skin with the cells removed and is supplied as human tissue rather than as an approved medical device. In October 2026 Korea's drug regulator said it is reviewing how such products are managed, and published clinical data are still limited, so ask the clinic exactly what is being injected and why.

The evidence for boosters is encouraging but modest: a 2024 review of polynucleotides found side effects mild and short-lived, in studies of low to moderate quality. Boosters work best as a course, so plan the first session in Seoul and ask whether the next ones can match a return trip. See Skin booster and Juvelook.

6. Body: smaller liposuction and shaping with fat

Liposuction is still the second most common operation worldwide, though ISAPS counted 11.4% fewer in 2025. In our Korean count, liposuction entries edged up from 16.3 to 19.5 per 1,000. Two Korean variations come up often in questions from Indonesian visitors: local-anaesthesia mini liposuction (known in Korea as LAMS), done awake for small areas, and huh-pa-go-ri (허파고리), which moves fat from the waist into the hip dip. LAMS entries held at about 2 per 1,000; huh-pa-go-ri entries are too few, 3 to 11 per half-year, to show a trend either way.

See Liposuction, Huh-pa-go-ri: waist-to-hip fat transfer and, when loose skin is the issue, Tummy tuck: mini, full or extended.

What this means for your trip

A trend tells you what other people are choosing, not what suits you. Use it to ask better questions:

• What will change, and what will not? A good consultation names the limits: how much grafted fat usually stays, how long threads or boosters last, whether a hump can be preserved.
• Which material, and why? Your own cartilage, donor cartilage or an implant; what happens if it ever needs to come out.
• Who operates, and who follows you up? Including after you are home in Indonesia.
• Bring your history. Earlier operation notes, implant details, photos and the medicines you take.
• Plan recovery before you book. Skin treatments fit a short stay; surgery on the nose, face or body needs time in Seoul before the flight. See Flying home after treatment, and check that your visa covers the stay in Entry rules and visas for Indonesian travellers.